Clinical trial · Interventional
Using the Conture® Multi-Lumen Balloon to Deliver Accelerated Partial Breast Brachytherapy
A Multi-site Prospective, Non Randomized Study Utilizing the Conture® Multi-Lumen Balloon (MLB) Breast Brachytherapy Applicator to Deliver Accelerated Partial Breast Irradiation: Analysis of Dosimetric Success, Local Tumor Control, Cosmetic Outcome, Acute and Chronic Toxicity, and Clinical Scenarios for Optimal Use
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This multiple site, prospective, non-randomized study has been designed to compile information on the efficacy of the Contura™ MLB in delivering APBI in appropriately selected patients through evaluation of dosimetric success as compared with a single central lumen balloon device and through treatment outcomes.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Conture Multi-Lumen Balloon | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- A
- description
- Conture Multi-Lumen Balloon
- interventionNames
- Device: Conture Multi-Lumen Balloon
Primary outcomes (1)
- measure
- Dosimetric efficacy of the Contura™ MLB with the historical efficacy rate of a single central lumen balloon device.
- timeFrame
- 5 years
Secondary outcomes (1)
- measure
- Quantify the dosimetric improvement of multi-lumen use over single lumen use through dosimetric comparison.
- timeFrame
- 5 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 50 Years
Show eligibility criteria text
Inclusion Criteria: * Able and willing to sign informed consent * Age 50 or older at diagnosis * Life expectancy greater than 10 years (excluding diagnosis of breast cancer). * Surgical treatment of the breast must have been lumpectomy. The margins of the resected specimen must be histologically free of tumor (negative surgical margins per NSABP criteria). * On histologic examination, the tumor must be DCIS or invasive breast carcinoma. For patients with invasive breast cancer, an axillary staging procedure must be performed. Either: 1. sentinel node biopsy (SNB) alone if sentinel node(s) is/are negative; or 2. axillary dissection (minimum of six axillary nodes removed); and 3. the axillary node(s) must be pathologically negative. * The T stage must be Tis, T1, or T2. If T2, the tumor must be ≤ 3.0 cm in maximum diameter. * Estrogen receptor positive tumor Exclusion Criteria: * Age \< 50 at diagnosis (regardless of histology) * Pregnant or breast-feeding (if appropriate, patient must use birth control during the study) * Active collagen-vascular disease * Paget's disease of the breast * History of DCIS or invasive breast cancer * Prior breast or thoracic RT for any condition * Multicentric carcinoma (DCIS or invasive) * Synchronous bilateral invasive or non-invasive breast cancer * Surgical margins that cannot be microscopically assessed or that are positive or close * Positive axillary node(s) * T stage of T2 with the tumor \> 3 cm in maximum diameter or a T stage \> 3 * Estrogen receptor negative tumor
References
Publications (1)
- DERIVEDCuttino LW, Arthur DW, Vicini F, Todor D, Julian T, Mukhopadhyay N. Long-term results from the Contura multilumen balloon breast brachytherapy catheter phase 4 registry trial. Int J Radiat Oncol Biol Phys. 2014 Dec 1;90(5):1025-9. doi: 10.1016/j.ijrobp.2014.08.341. Epub 2014 Oct 13. PMID 25442036